Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Captain Haddock's health issues in the adventures of Tintin. Comparison with Tintin's health issues.

Caumes E, Epelboin L, Guermonprez G, Leturcq F, Clarke P.

Presse Med. 2016 Jul-Aug;45(7-8 Pt 1):e225-32. doi: 10.1016/j.lpm.2016.02.027. Epub 2016 Jul 21.

PMID:
27453541
2.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

3.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

4.

Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.

Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F; French ANRS HIV-2 CO5 Cohort.

Clin Infect Dis. 2012 Nov 15;55(10):1417-25. doi: 10.1093/cid/cis708. Epub 2012 Aug 20.

PMID:
22911639
5.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration.

AIDS. 2012 Aug 24;26(13):1691-705.

6.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration.

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

7.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

8.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration, Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.

AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283.

9.
10.

A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections.

Dautzenberg B, Truffot-Pernot C, Hazebroucq J, Legris S, Guérin C, Begelman C, Guermonprez G, Fievet MH, Chastang C, Grosset J.

Infection. 1997 Jan-Feb;25(1):16-21.

PMID:
9039532
11.

A life-threatening adverse reaction during trimethoprim-sulfamethoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus.

Caumes E, Guermonprez G, Winter C, Katlama C, Bricaire F.

Clin Infect Dis. 1996 Dec;23(6):1313-4. No abstract available.

PMID:
8953079
12.

Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis.

Caumes E, Bocquet H, Guermonprez G, Rogeaux O, Bricaire F, Katlama C, Gentilini M.

Clin Infect Dis. 1995 Sep;21(3):656-8.

PMID:
8527561
13.

Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit.

Caumes E, Carrière J, Guermonprez G, Bricaire F, Danis M, Gentilini M.

Clin Infect Dis. 1995 Mar;20(3):542-8.

PMID:
7756473
14.

Disseminated Penicillium marneffei infection associated with human immunodeficiency virus: a report of two cases and a review of 35 published cases.

Hilmarsdottir I, Meynard JL, Rogeaux O, Guermonprez G, Datry A, Katlama C, Brücker G, Coutellier A, Danis M, Gentilini M.

J Acquir Immune Defic Syndr. 1993 May;6(5):466-71. Review.

PMID:
8483110
15.

AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin.

Caumes E, Guermonprez G, Katlama C, Gentilini M.

AIDS. 1992 Dec;6(12):1483-7.

PMID:
1283521
16.

Cutaneous side-effects of bleomycin in AIDS patients with Kaposi's sarcoma.

Caumes E, Katlama C, Guermonprez G, Bournerias I, Danis M, Gentilini M.

Lancet. 1990 Dec 22-29;336(8730):1593. No abstract available.

PMID:
1701510

Supplemental Content

Loading ...
Support Center